Similarly, in murine models of human non-small cell lung cancer, treatment with vandetanib and cediranib initially led to tumor regression followed by resistance to therapy and progression that was associated with upregulation of both HGF and its receptor, c-MET [21]. The gene discussed is HGF; the disease is non-small cell lung carcinoma.